Azathioprine and allopurinol: A two-edged interaction

Journal of Gastroenterology and Hepatology (Australia)

Volumn 25, Issue 4, 2010, Pages 653-655

  Gearry, Richard B ^a,b   Day, Andrew S ^a,b   Barclay, Murray L ^a,b,c   Leong, Rupert W L ^d   Sparrow, Miles P ^e  

^a UNIVERSITY OF OTAGO   (New Zealand)

^b Department of Paediatrics University of Otago ^*  (New Zealand)

^c CHRISTCHURCH HOSPITAL   (New Zealand)

^d ALFRED HOSPITAL   (Australia)

^e Department of Microbiology and Infectious Diseases   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

6 METHYLTHIOINOSINE; ALLOPURINOL; AZATHIOPRINE; MERCAPTOPURINE; PREDNISOLONE;

ASIA; CROHN DISEASE; DOSE RESPONSE; DRUG ANTAGONISM; DRUG BLOOD LEVEL; DRUG DOSE REDUCTION; DRUG METABOLISM; DRUG SAFETY; EDITORIAL; ENTERITIS; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; LIVER TOXICITY; PACIFIC ISLANDS; PRESCRIPTION; PRIORITY JOURNAL; SINGLE NUCLEOTIDE POLYMORPHISM; ULCERATIVE COLITIS;

EID: 77950172740     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/j.1440-1746.2010.06254.x     Document Type: Editorial

References (16)

1. Anonymous. NSW Health Safety Notice. Allopurinol and Azathioprine. A Serious and Known Drug Interaction. 2009 011/09: pp 1 2. Cited 11 Nov 2009. Available from URL: http://www.health.nsw.gov.au/resources/quality/sabs/pdf/ sn20090507.pdf.
2. Dubinsky MC, Yang H, Hassard PV et al. 6-MP metabolite profiles provide a biochemical explanation for 6-MP resistance in patients with inflammatory bowel disease. Gastroenterol 2002 122 : 904 915.
3. Gardiner SJ, Gearry RB, Burt MJ, Ding SL, Barclay ML. Severe hepatotoxicity with high 6-methylmercaptopurine nucleotide concentrations after thiopurine dose escalation due to low 6-thioguanine nucleotides. Eur. J. Gastroenterol. Hepatol. 2008 20 : 1238 1242.
4. Sparrow MP, Hande SA, Friedman S, Cao D, Hanauer SB. Effect of allopurinol on clinical outcomes in inflammatory bowel disease nonresponders to azathioprine or 6-mercaptopurine. Clin. Gastroenterol. Hepatol. 2007 5 : 209 214.
5. Sparrow MP, Hande SA, Friedman S et al. Allopurinol safely and effectively optimizes tioguanine metabolites in inflammatory bowel disease patients not responding to azathioprine and mercaptopurine. Aliment. Pharmacol. Ther. 2005 22 : 441 446.
6. Chocair P, Duley J, Simmonds HA et al. Low-dose allopurinol plus azathioprine/cyclosporin/prednisolone, a novel immunosuppressive regimen. Lancet 1993 342 : 83 4.
7. Leong RW, Gearry RB, Sparrow MP. Thiopurine hepatotoxicity in inflammatory bowel disease: the role for adding allopurinol. Expert Opin. Drug Saf. 2008 7 : 607 616.
8. Leung Y, Sparrow MP, Schwartz M, Hanauer SB. Long term efficacy and safety of allopurinol and azathioprine or 6-mercaptopurine in patients with inflammatory bowel disease. J. Crohns. Colitis. 2009 3 : 162 167.
9. Witte TN, Ginsberg AL. Use of allopurinol with low-dose 6-mercaptopurine in inflammatory bowel disease to achieve optimal active metabolite levels: a review of four cases and the literature. Can. J. Gastroenterol. 2008 22 : 181 185.
10. Rahhal RM, Bishop WP. Initial clinical experience with allopurinol-thiopurine combination therapy in pediatric inflammatory bowel disease. Inflamm. Bowel Dis. 2008 14 : 1678 1682.
11. Ansari A, Elliott T, Baburajan B et al. Long-term outcome of using allopurinol co-therapy as a strategy for overcoming thiopurine hepatotoxicity in treating inflammatory bowel disease. Aliment. Pharmacol. Ther. 2008 28 : 734 741.
12. Gearry RB, Barclay ML. Azathioprine and 6-mercaptopurine pharmacogenetics and metabolite monitoring in inflammatory bowel disease. J. Gastroenterol. Hepatol. 2005 20 : 1149 1157.
13. Collie-Duguid ES, Pritchard SC, Powrie RH et al. The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations. Pharmacogenetics 1999 9 : 37 42.
14. Efrati E, Adler L, Krivoy N, Sprecher E. Distribution of TPMT risk alleles for thiopurine [correction of thioupurine] toxicity in the Israeli population. Eur. J. Clin. Pharmacol. 2009 65 : 257 262.
15. Cooper SC, Ford LT, Berg JD, Lewis MJ. Ethnic variation of thiopurine S-methyltransferase activity: a large, prospective population study. Pharmacogenomics 2008 9 : 303 309.
16. Kudo M, Moteki T, Sasaki T, et al. Functional characterization of human xanthine oxidase allelic variants. Pharmacogenet. Genomics. 2008 18 : 243 251.